Skip to content

Basket

You currently have no items in your basket.

Research-Grade Biosimilar Monoclonal Antibodies

From Bio X Cell

Bio X Cell InVivoSIM™ non-therapeutic antibodies are research-grade biosimilar monoclonal antibodies that have the same active biological component as the original therapeutic antibodies. Biosimilars make it possible to study the biological effects of a drug without the need to source an expensive pharmaceutical-grade therapeutic.

Our InVivoSIM™ antibodies feature greater than 95% purity and are free of preservatives, stabilizers, and carrier proteins. InVivoSIM™ antibodies are screened for murine pathogens and protein aggregation, feature binding validation via Immunoblot and are guaranteed to contain less than 1 endotoxin unit per milligram. InVivoSIM™ antibodies are for Research Use Only (RUO) and are not for therapeutic use.

Product Name Application InVivoSIM™ SKU
InVivoSIM™ anti-human CD20 (Rituximab Biosimilar) FC; ELISA; WB SIM0008
InVivoSIM™ anti-human CTLA-4 (Ipilimumab Biosimilar) CTLA-4 neutralization; FC; ELISA; WB SIM0004
InVivoSIM™ anti-human EGFR (Cetuximab Biosimilar) GFR blockade; ELISA; FC SIM0002
InVivoSIM™ anti-human HER2 (Trastuzumab Biosimilar) FC; ELISA; IHC; WB SIM0005
InVivoSIM™ anti-human PD-1 (Nivolumab Biosimilar) Blocking of PD-1/PD-L signaling; FC; IHC; WB SIM0003
InVivoSIM™ anti-human PD-L1 (Atezolizumab Biosimilar) FC; WB SIM0009
InVivoSIM™ anti-human TNFα (Adalimumab Biosimilar) TNFα neutralization; FC, ELISA; IF; IP; IHC; WB SIM0001
InVivoSIM™ anti-human TNFα (Infliximab Biosimilar) TNFα neutralization; FC; ELISA; WB SIM0006
InVivoSIM™ anti-human VEGF (Bevacizumab Biosimilar) VEGF neutralization; FC; ELISA; IP SIM0007

IF Immunofluorescence | IHC-F Immunohistochemistry (frozen) | IHC-P Immunohistochemistry (parrafin) | WB Western blot | IP Immunoprecipitation | FC Flow cytometry (requires flurochrome conjugation)

Don’t see the antibody of your interest? Contact us for more information:

We use cookies to give you the best experience of using this website. By continuing to use this site, you accept our use of cookies. Please read our Cookie Policy for more information.